Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stentrelated Symptoms:A Meta-analysis of Randomized Controlled Studies

This study aimed to evaluate the effectiveness of tamsulosin monotherapy for the treatment of ureteral stent-related symptoms(SRSs)and compare it with that of solifenacin monotherapy and combined therapy of tamsulosin and silifenacin.Randomized controlled trials(RCTs),which evaluated the effectiveness of tamsulosin for the treatment of SRSs,were searched from the databases PubMed,EMBASE and the Cochrane Library published up to November 2018.Eight RCTs involving 1087 participants were finally included in this meta-analysis.The results showed that tamsulosin monotherapy could significantly decrease the urinary symptoms[mean difference(MD)—7.56,95%confidence interval(CI)(-11.47,-3.65),P=0.0001]and body pain[MD-5.25,95%CI(-8.03,-2.46),P=0.0002],and improve the sexual performance[MD-1.06,95%CI(-1.89,-0.24),P=0.01]compared with the control group.Moreover,there was no significant difference between tamsulosin monotherapy and solifenacin monotherapy in all outcomes except for significantly better sexual performance in solifenacin group[MD 0.29,95%CI(0.06,0.51),P=0.01].In addition,the effectiveness of combined therapy of tamsulosin and solifenacin was not superior to that of tamsulosin monotherapy.Our study demonstrated that tamsulosin monotherapy was effective for the treatment of patients with SRSs;evident superiority could not be found for therapy of tamsulosin and solifenacin combined.

Effect of tamsulosin on ejaculatory function in BPH/LUTS

This study was undertaken to determine the impact on ejaculatory function of tamsulosin （0.2 mg） given once daily （OD） for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score （IPSS） ≥ 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire （MSHQ）, and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains （EFD, EjFD, SDA and ADD） or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction （EjD） was 13.4%. Incidences of the seven different types of EjD （decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation） were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for I PSS responders than for non-responders （26.09 vs. 24.06, P=0.03）. An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques

The aim of the present study was to develop tamsulosin hydrochloride sustained-release pellets using two-layered membrane techniques.Centrifugal granulator and fluidizedbed coater were employed to prepare drug-loaded pellets and to employ two-layered membrane coating respectively.The prepared pellets were evaluated for physicochemical characterization,subjected to differential scanning calorimetry(DSC)and in vitro release of different pH.Different release models and scanning electron microscopy(SEM)were utilized to analyze the release mechanism of Harnual■ and home-made pellets.By comparing the dissolution profiles,the ratio and coating weight gain of Eudragit■ NE30D and Eudragit■ L30D55 which constitute the inside membrane were identified as 18:1 and 10%-11%.The coating amount of outside membrane containing Eudragit■ L30D55 was determined to be 0.8%.The similarity factors(f_(2))of home-made capsule and commercially available product(Harnual■)were above 50 in different dissolution media.DSC studies confirmed that drug and excipients had good compatibility and SEM photographs showed the similarities and differences of coating surface between Harnual■ and self-made pellets before and after dissolution.According to Ritger-Peppas model,the two dosage form had different release mechanism.

Effect of tamsulosin versus tamsulosin plus tadalafil on renal calculus clearance after shock wave lithotripsy:An open-labelled,randomised,prospective study

Objectives:To compare the efficacy of tamsulosin versus tamsulosin plus tadalafil in achieving clearance of fragments after shock wave lithotripsy(SWL)to treat renal calculi.Methods:Between January 2016 to December 2017,140 patients with solitary,non-branched,non-lower calyceal renal calculus and measuring less than 20 mm and treated with SWL were randomized to tamsulosin(group A)or tamsulosin plus tadalafil(group B).Therapy was given for a period of 4 weeks.Stone clearance rate,analgesic requirement,occurrence of steinstrasse,need for auxiliary procedures(endoscopic treatment),and adverse effects of drugs were recorded.Results:The overall clearance rate was 72.5%(50/69)in the group A and 90.1%(64/71)in the group B(pZ0.007).For stones up to 12 mm,the difference in the clearance rate was significant(pZ0.039)while it was not so for stones larger than 12 mm(pZ0.151).There was no statistically significant difference between the two groups with regards to analgesic requirement(pZ0.94),occurrence of steinstrasse(pZ0.101),need for auxiliary procedures(pZ0.76),and adverse effects of the drugs(pZ0.148).Conclusion:Our study shows that adjunctive medical expulsive therapy with tamsulosin and tadalafil achieves better clearance rate than tadalafil alone in patients receiving SWL for renal stones.

Stability Indicating HPLC Method for Quantification of Solifenacin Succinate &Tamsulosin Hydrochloride along with Its Impurities in Tablet Dosage Form

A novel stability-indicating RP-HPLC method was developed and validated for simultaneous determination of Solifenacin Succinate & Tamsulosin Hydrochloride and its impurities in tablet dosage form. The method was developed using L1 column with gradient using the mobile phase consist of solvent-A (pH = 6.6, phosphate buffer + 0.5% Triethylamine) and solvent-B (90% Acetonitrile). The eluted compounds were monitored at 225 nm. Solifenacin Succinate & Tamsulosin Hydrochloride was subjected to oxidative, acid, base, hydrolytic, thermal and photolytic stress conditions. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantitation, accuracy, precision and robustness. The limit of quantification results was ranged from 0.135 - 0.221 μg/mL for Solifenacin Succinate impurities and 0.043 - 0.090 μg/mL for Tamsulosin Hydrochloride impurities. This method is suitable for the estimation of impurities and assay of Solifenacin Succinate & Tamsulosin Hydrochloride in tablets dosage form.

Neuroprotective effects of tamsulosin on intracerebral hemorrhage

The alpha1 adrenoreceptor antagonist tamsulosin is primarily used to treat benign prostatic hypertrophy. In this study, we intragastrically administered rats with 0.01,0.1 and 1 mg/kg tamsulosin to investigate the effects of tamsulosin on memory function, and hippocampal cell apoptosis and proliferation following intracerebral hemorrhage. Step-down avoidance task results showed that tamsulosin treatment markedly alleviated intracerebral hemorrhage- induced short-term memory impairment. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling results showed that tamsulosin treatment markedly suppressed intracerebral hemorrhage-induced caspase-3 expression in the hippocampal CA1 region and cell proliferation in the hippocampal dentate gyrus. Tamsulosin treatment at a dose of 0.01 mg/kg exhibited the most potent inhibitory effects on cell apoptosis and proliferation. These findings suggest that tamsulosin treatment facilitates the recovery of rat memory function by inhibiting hippocampal cell apoptosis and proliferation followincl intracerebral hemorrhaQe.

HPLC Method for the Determination of Tamsulosin Hydrochloride in Sustained Release Tablets

The development and validation of an isocratic high performance liquid chromatographic method is described for the determination of tamsulosin hydrochloride in sustained release tablets. The determination was performed on a Diamonsil BDS C18 column with a mobile phase consisting of a mixture of acetonitrile, methanol and 0 5% phosphoric acid solution (20∶30∶50, V/V/V ) at a flow rate of 1 0 mL/min. UV detection was made at 274 nm. The linear range for tamsulosin hydrochloride was 0 81-8 10 μg/mL. The mean recovery was 99 8% ( S R=0 7%, n =9), and the precision was found to be 0 45% ( n =9). The proposed method can be used for routine analysis of tamsulosin hydrochloride in sustained release tablets.

Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury:A case report

BACKGROUND Tamsulosin,a selectiveα1-adrenergic receptor antagonist,is commonly used for treating neurogenic bladder in patients with spinal cord injury(SCI).No severe adverse events have been described with such tamsulosin use.To our knowledge,we report the first case of severe life-threatening hypotension as an adverse effect of tamsulosin in a person with SCI.Therefore,we report this case to inform that this severe adverse effect of tamsulosin can occur when treating patients with SCI.CASE SUMMARY A 59-year-old woman was diagnosed with cervical spinal cord myelopathy and was classified as American Spinal Injury Association Impairment Scale D,neurological level of injury C3.Because she suffered from voiding difficulty due to neurogenic bladder,we prescribed tamsulosin.Her vital signs remained stable,but occasional hypotensive symptoms followed defecation.We reduced the dose of tamsulosin,but after administering tamsulosin for 9 d,she experienced lifethreatening hypotension with no evidence of hypovolemic shock,neurogenic shock,cardiogenic shock,or septic shock.A hypotensive condition induced by tamsulosin was the suspected cause,and her symptoms could be associated with adverse effects of tamsulosin.As symptoms resolved after stopping tamsulosin,and no other reason was found,we concluded that tamsulosin was the cause of her symptoms.CONCLUSION Caution for severe hypotension is needed when administering tamsulosin for neurogenic bladder in a patient with SCI.

The Effect of Switching Patients with Symptomatic Benign Prostatic Hyperplasia from Tamsulosin 0.2 mg to 0.4 mg

Objectives: In 2010, tamsulosin 0.2 mg (OD) was withdrawn from Thailand and replaced with tamsulosin 0.4 mg (OD). Therefore, we assessed the impact of this change on the patients, at a men’s health clinic, with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Material and Methods: Subjects were 100 men with BPH who had been taking tamsulosin 0.2 mg as needed for at least 3 months. The outcome measures were IPSS, AMS and IEFF5 scores and uroflowmetry. Tolerability was evaluated on by adverse events. Changes from baseline were assessed using the paired t-test. SPSS version 12.0 was used for statistical analysis, with p 0.05 considered significant. Results: The mean follow up of tamsulosin 0.2 and 0.4 mg were 20.23 and 10.56 months respectively. On switching from tamsulosin 0.2 to 0.4 mg, mean IPSS score improved from 15.54 ± SD 1.25 to 14.13 ± SD 1.09 (p = 0.034), Q max 15.91 cm3/sec ± SD 1.36 to 16.69 cm3/sec ± SD 1.52 (p = 0.128), and nocturia 3.15 ± SD 0.32 to 2.68 ± SD 0.39 (p = 0.015), respectively. However IEFF-5 score and AMS score increased from14.78 ± SD 1.38 to 15.79 ± SD 1.03 (p = 0.0055) and 34.76 ± SD 2.76 to 33.21 ± SD 2.62 (p = 0.0853), respectively. Treatment-related adverse events of Tamsulosin 0.2 mg included dizziness (4%), postural hypotension (3%) and retrograde ejaculation (3%). Interestingly, no withdrawals resulted from adverse events during Tamsulosin 0.4 mg assessment. Conclusions: Switching to tamsulosin 0.4 mg improves LUTS. The change was well tolerated by the majority of patients. Increased symptoms scores of erectile dysfunction and aging male during the study may be due to increased age.

Efficiency of Tamsulosin after Shockwave Lithotripsy for the Treatment of Lower Ureteric Stone: Alkaramah Teaching Hospital Experience, Iraq

Background: Stone disease is a wide health problem;certain drugs have been used as supplement with ESWL for the treatment of symptomatic uncomplicated lower ureteric stone like Nefidipine, Alfuzosin and Tamsulosin. The purpose of this study is to evaluate the efficacy of Tamsulosin for the treatment of lower ureteric stone of 5 - 10 mm diameter after ESWL. Methods: A total of 105 patients with lower ureteric stone of less than 10 mm diameters were divided into two groups. Group 1 including 48 patients received 0.4 mg Tamsulosin and diclofenac sodium analgesia as needed immediately after ESWL and continued until stone expulsion was confirmed up to maximum of 30 days. Group 2 including 47 patients was given diclofenac sodium only as needed after ESWL. Result: 46 of 49 patients in group 1 and 44 of 48 patients in group 2 ultimately passed stones. The number of ESWL sessions was 1.4 ± 0.6 in group 1 & 1.42 ± 0.75 in group 2. There were 10 patients who needed analgesia after ESWL in group 1 and 17 patients in group 2. Visual analogue scale pain severity score was 5.32 ± 1.23 and 6.41 ± 1.26 in group 1 and 2, respectively. The time to stone expulsion in group 1 and 2 was 8 ± 5.4 days and 12 ± 10.3 days, respectively. No significant complications or side effects occurred. Conclusion: The use of Tamsulosin in combination with ESWL in patients with lower ureteric stone of 5 - 10 mm was effective for reducing the time to stone expulsion, decreasing need for analgesia, and facilitating stone passage without significant improvement in stone free rate.

A Study to Compare the Safety and Efficacy of Solifenacin, Tamsulosin and Tadalafil in Relieving Double-J Stent Related Symptoms

Objective: To evaluate and compare the safety and efficacy of Solifenacin, Tamsulosin, and Tadalafil in treating ureteral stent related symptoms (SRS) in patients with indwelling Double-J ureteral stents. Materials and Methods: A prospective randomized controlled study was conducted on 146 consecutive patients in the department of urology, Government Stanley Medical College & Hospital, Chennai, Tamilnadu, India between Sept 2017-March 2019, with SRS after taking informed consent and confirming DJ Stent position by X-ray KUB post-operatively. Patients were randomized into 4 groups: Group A (Placebo), Group B (Solifenacin 5 mg), and Group B (Tamsulosin 0.4 mg) and group D (Tadalafil 5 mg) at end of 1st week till the removal of DJ stent at end of 3 weeks. All patients were assessed for bothersome lower urinary tract symptoms (LUTS) using the validated Ureteral Stent Symptom Questionnaire (USSQ) at 1st week and 3 weeks after the starting of medications. Appropriate statistical analysis as carried out and the level of significance was set at P Results: LUTS, general health, and work performance improved with Solifenacin, Tamsulosin and Tadalafil and all the three were comparable in relieving urinary symptoms. Tadalafil was better at relieving body pain, additional problems and sexual problems better than Tamsulosin. Tadalafil showed comparable improvement in LUTS, better sexual health and decreased body pain compared to solifenacin, whereas the latter had better general health, additional problems & work performance scores. Conclusion: Solifenacin is more effective than Tamsulosin in alleviating LUTS associated with SRS and both show a distinctive advantage over placebo. PDE inhibitor Tadalafil can also be tried for SRS and is as effective as antimuscarinics and α-blockers in relieving urinary symptoms and is more efficacious in relieving sexual symptoms and body pain.

Clinical study of combination therapy of tamsulosin and solifenacin for benign prostatic hyperplasia with overactive bladder

Objective To evaluate the efficacy and safety of combination therapy of tamsulosin and solifenacin for benign prostatic hyperplasia ( BPH) with overactive bladder ( OAB) . Methods 82 patients with OAB and coexisting BPH were randomly divided into tamsulosin group ( n

Efficacy of solifenacin with or without tamsulosin in patients with overactive bladder

Objective To evaluate the efficacy of sollfenacin with or without tamsulosin in patients with overactive bladder ( OAB ) . Methods Fifty-three patients with OAB were randomly divided into two groups ( group

Tamsulosin as medical expulsive therapy for lower ureterolithiasis:A meta-analysis

Objective: To review the evidence for tamsulosin as medical expulsive therapy in enhancing the effectiveness of distal ureteral stone clearance rate. Methods: We searched Pubmed/Medline, Embase, CBM and the Cochrane Library up to October 2011. All randomized controlled trials in which tamsulosin was evaluated with distal ureterolithiasis were eligible for the analysis. Outcome measure assessed was stone clearance rate. Two authors independently assessed study quality and extracted data. All data were analyzed using RevMan 5.1. Results: Thirteen studies involving 1067 participants met the inclusion criteria. Study duration ranged from 7 to 42 d. The pooled analysis showed an improvement of 41% in stone clearance rate of tamsulosin as medical expulsive therapy for distal ureteral calculi (RR=1.41, 95% CI=1.18 to 1.70). According to stone size (6 mm<size<10 mm, 5 mm<size<6 mm, size <5 mm), the pooling effects of tamsulosin were analyzed, with a higher stone expulsion rate obtained than control (RR=1.52, 1.75, 1.05, 95% CI=1.30 to 1.77, 1.25 to 2.45, 0.95 to 1.16, respectively). Adverse effects of tamsulosin, mainly retrograde ejaculation, dizziness and hypotension, were reported in 7 included trials. Conclusion: Treatment with tamsulosin appears to be a safe and effective medical expulsion therapy for distal ureterolithiasis. To make a definite clinical recommendation to use tamsulosin as medical expulsive treatment for distal ureteral calculi, high quality multicentric, randomized, double blinded, controlled trials are necessary to prove its efficacy.

灵泽片联合盐酸坦洛新治疗良性前列腺增生患者短期疗效观察

目的探讨灵泽片联合盐酸坦洛新治疗良性前列腺增生患者的短期疗效。方法将收治的86例老年良性前列腺增生患者分为对照组(43例)和观察组(43例)。对照组口服盐酸坦洛新胶囊治疗,观察组口服盐酸坦洛新胶囊和灵泽片,连续治疗12周,比较两组疗效,评估国际前列腺症状评分(IPSS)和生活质量指数(QOL)评分、测定膀胱残余尿量(PVR)、最大尿流率(Qmax)、前列腺体积(PV)、总前列腺特异性抗原(tPSA)、游离前列腺特异性抗原(fPSA)水平以及白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平。结果治疗后观察组总有效率高于对照组(P<0.05);治疗后对照组和观察组患者IPSS评分、QOL评分、PVR、PV、IL-6和TNF-α水平以及fPSA和tPSA水平均较治疗前降低,且观察组低于对照组(P<0.05)。治疗后对照组和观察组患者Qmax较治疗前升高,且观察组高于治疗组(P<0.05)。结论灵泽片联合盐酸坦洛新可降低良性前列腺增生患者炎症反应,改善临床指标和前列腺功能。

Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones

Background Tamsulosin, an alpha-1 receptor antagonist, has been demonstrated effective in promoting distal ureteral stone passage and in reducing pain associated with stone expulsion. This study aimed to evaluate the effect of tamsulosin in comparison with nifedipine and extracorporeal shock wave lithotripsy （ESWL） on the expulsion rate of distal ureteral stones at different sizes. Methods We assigned 314 patients to three categories： Ⅰ, the stone with maximal diameter of 4.0-5.9 mm; Ⅱ, 6.0-7.9 mm, and Ⅲ, 8.0-9.9 mm. Patients in each category were randomly subdivided into three treatment subgroups： group A （nifedipine group）, group B （tamsulosin group）, and group C （ESWL group）. Stone-free rate and the dose of analgesics were recorded weekly during the 4-week follow-up period. Results Three hundred and three patients completed the study. The results showed that nifedipine and tamsulosin treatments promoted a small （4-8 mm, categories Ⅰ and Ⅱ） stone expulsive rate that was comparable with ESWL treatment. Nonetheless, when the stone diameter was 8.0-9.9 mm, ESWL showed a greater stone free rate than nifedipine and tamsulosin treatments; no significant difference existed between the latter two therapies. Although the ESWL treatment group required the least analgesics, tamsulosin treatments required less pain medication than nifedipine （P 〈0.05）. Conclusions Tamsulosin treatment is recommended for patients with the stone diameter smaller than 8 mm because of its feasibility, effectiveness and safety. ESWL is more appropriate than tamsulosin therapy for the patients whose stones are larger than 8 mm.

Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia： data from China

Background Tamsulosin hydrochloride can significantly improve benign prostatic hyperplasia （BPH） symptoms after the first dose and achieve long-term efficacy in European and American populations; however, the coresponding studies from China are rarely seen. The purpose of this study was to evaluate the long-term efficacy and safety of tamsulosin hydrochloride 0.2 mg once daily in patients with lower urinary tract symptoms （LUTS） suggestive of BPH in China. Methods Chinese patients with LUTS suggestive of BPH were enrolled in a 4-week placebo run-in period and subsequent 60-week open-label study. Tamsulosin hydrochloride 0.2 mg was administered daily during the period of the study. The efficacy and safety parameters were evaluated at the end of treatment period I （0-12 weeks） and period II （13-60 weeks）. The BPH patients were divided into tamsulosin monotherapy group and combination therapy group which received concomitant medication of finasteride 5 mg once daily after the evaluation at the end of treatment period I. Results A total of 113 patients were recruited to the study. Eighty-two patients received tamsulosin monotherapy and twenty-nine received combination therapy during the treatment period I1. Tamsulosin hydrochloride produced a great improvement in mean maximum urinary flow rate （Qmax） （1.7 ml/s, 3 ml/s） and a significant decrease in mean international prostate symptom score （IPSS） （4.1,6.4） after 12-week and 60-week treatments, respectively. At the end of treatment period II, there were significant improvement in IPSS, quality of life （QOL） score, Qmax and average flow rate （eave） for combination therapy group compared with the treatment period I （all P 〈0.05）. No serious adverse events （SAE） were recorded during the study. Conclusion Long-term tamsulosin hydrochloride therapy is a safe, effective and well-tolerated method for the treatment for LUTS suggestive of BPH in China.

Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia： a meta analysis

Background Pharmacological therapy has been considered as the first-line treatment for patients with uncomplicated benign prostatic hyperplasia （BPH）. The aim of this study was to evaluate the efficacy and safety of tamsulosin compared with a placebo for treating BPH. Methods The randomized placebo-controlled trials （RCT） of tamsulosin for the treatment of BPH from all over the world were searched. PubMed, Ovid, ScienceDirect, EBSCO, CBM, and CNKI were searched, as well as a manual search of four Chinese journals： Chinese Journal of Andrology, National Journal of Andrology, Chinese Journal of Urology, and Journal of Clinical Urologywas also performed. Two reviewers independently screened the studies for eligibility, evaluated the quality and extracted the data from the eligible studies, with confirmation by cross-checking. Divergences of opinions were settled by discussion. Meta-analysis was processed by Rev Man 5.0 software, fail-safe number was performed by SASS.0 software. Results Seven RCTs involving 2455 men met the inclusion criteria. The basic characteristics of patients were comparable in all the studies. Comparing three common criteria： international prostate symptom score （IPSS）/Boyarsky symptom score, maximum flow rate （MFR）, quality of life （QOL）, tamsulosin was better than placebo at improving IPSS and MFR, with no significant difference in the QOL. Adverse events of tamsulosin also showed no significant difference from the placebo group （Z=1.62, P=0.10, OR=1.22, 95% Cl 0.96-1.54）. Conclusions Tamsulosin is better than placebo at improving IPSS and MFR. Adverse events of tamsuloisn show no significant difference compared with placebo. More high quality trials with larger samples and longer follow-up are proposed.

八正片联合坦洛新片治疗输尿管壁内段结石的效果

目的探讨八正片联合坦洛新片治疗输尿管壁内段结石的临床疗效。方法选取确诊输尿管壁内段结石的患者93例,其中90例患者符合纳入标准,用随机分组法分为对照组(n=45)和观察组(n=45)。2组患者采用体外冲击波碎石后,对照组患者口服坦洛新片,观察组口服八正片联合坦洛新片,均持续治疗15 d。治疗后,评估2组患者的临床疗效。比较2组中医证候积分及结石排净率;统计2组肾绞痛发作率、抗生素使用率、止痛药使用率、结石排净时间、抗生素使用时间及视觉模拟疼痛(visual analogue scale,VAS)评分;比较2组患者治疗前后的肾功能指标(肌酐、尿素氮)及尿生化指标(尿酸、尿草酸和尿钙)水平。记录2组治疗期间并发症发生情况。结果观察组的治疗有效率(95.56%)高于对照组(82.22%),P<0.05;观察组各项中医证候积分明显低于对照组,且各时间点结石排净率均高于对照组(P<0.05);观察组肾绞痛发作率、抗生素使用率、止痛药使用率、结石排净时间、抗生素使用时间及用药3、5 d的VAS评分明显低于对照组(P<0.05);观察组输尿管壁内段结石患者肌酐、尿素氮及尿酸、尿草酸和尿钙水平明显低于对照组(P<0.05);观察组并发症的发生率为15.56%,高于对照组的11.11%(P>0.05)。结论八正片联合坦洛新片治疗输尿管壁内段结石疗效显著,可缓解症状,提高结石排净率。

盐酸坦索罗辛、前列倍喜、针灸三联疗法对ⅢB型慢性前列腺炎患者血清免疫和炎症指标的影响

目的探究盐酸坦索罗辛、前列倍喜、针灸三联疗法对ⅢB型慢性前列腺炎患者血清免疫和炎症指标的影响。方法选取ⅢB型慢性前列腺炎患者120例,随机均分为对照组(盐酸坦索罗辛+前列倍喜)及三联组(盐酸坦索罗辛+前列倍喜+针灸)。比较两组临床疗效、治疗前后中医证候评分、美国国立卫生研究院慢性前列腺炎症指数(NIH-CPSI)评分、血清免疫指标[免疫球蛋白(Ig)A、IgM、IgG]和炎症指标[肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-2、IL-8、IL-10]水平。结果治疗后,三联组治疗总有效率高于对照组(P<0.05)。与治疗前比较,治疗后两组中医证候评分、NIH-CPSI评分、TNF-α、IL-2及IL-8降低,IgA、IgM、IgG升高,且三联组较对照组更为显著(P<0.05)。与治疗前比较,治疗后两组IL-10升高(P<0.05),但两组间比较差异无显著性(P>0.05)。结论盐酸坦索罗辛、前列倍喜、针灸三联疗法对ⅢB型慢性前列腺炎患者临床疗效显著,可明显改善其血清免疫和炎症指标。